author-photo

Ute Klinkhardt

Merck KGaA

15

Papers

299

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

2019 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (38)
ARN POUR LA CANCÉROTHÉRAPIE

2018
Show All
- Source
- Cite
- Save
Citations (0)
1305TiPPhase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC: Topic: IT Clinical

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1155PResults of an open label randomized phase II trial of CV9104, an mRNA-based multivalent cancer immunotherapy in patients (pts) with intermediate or high risk localized prostate cancer (PC) undergoing radical prostatectomy (RPE)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1149PResults of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses

2016 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis.

2016 Journal of Clinical Oncology
- Martin Sebastian
- Ute Klinkhardt
Show All
- Source
- Cite
- Save
Citations (1)
The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow

2015 Platelets
Show All
- Source
- Cite
- Save
Citations (3)